Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 2
2004 4
2005 3
2006 6
2007 7
2008 4
2009 2
2010 2
2011 1
2012 2
2013 3
2014 4
2015 3
2016 4
2017 3
2018 3
2019 4
2020 7
2021 10
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy.
Caggiano G, Fioriti S, Morroni G, Apollonio F, Triggiano F, D'Achille G, Stefanizzi P, Dalfino L, Ronga L, Mosca A, Sparapano E, De Carlo C, Signorile F, Grasso S, Barchiesi F, Montagna MT. Caggiano G, et al. Among authors: barchiesi f. J Infect Public Health. 2024 Apr 12;17(6):967-974. doi: 10.1016/j.jiph.2024.04.009. Online ahead of print. J Infect Public Health. 2024. PMID: 38631066 Free article.
Candida auris: the new fungal threat.
Pallotta F, Viale P, Barchiesi F. Pallotta F, et al. Among authors: barchiesi f. Infez Med. 2023 Sep 1;31(3):323-328. doi: 10.53854/liim-3103-6. eCollection 2023. Infez Med. 2023. PMID: 37701386 Free PMC article. Review.
Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic.
Giannella M, Verardi S, Karas A, Abdel Hadi H, Dupont H, Soriano A, Santerre Henriksen A, Cooper A, Falcone M; ARES Study Group. Giannella M, et al. Open Forum Infect Dis. 2023 Jul 4;10(7):ofad329. doi: 10.1093/ofid/ofad329. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37496600 Free PMC article.
Kaposi Sarcoma in People Living with HIV: Is it Water under the Bridge?
Papalini C, Brescini L, Curci L, Bastianelli S, Barchiesi F, Giacometti A, Francisci D. Papalini C, et al. Among authors: barchiesi f. Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023027. doi: 10.4084/MJHID.2023.027. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37180210 Free PMC article. No abstract available.
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
Meschiari M, Cozzi-Lepri A, Cervo A, Granata G, Rogati C, Franceschini E, Casolari S, Tatarelli P, Giacobbe DR, Bassetti M, Pinna SM, De Rosa FG, Barchiesi F, Canovari B, Lorusso C, Russo G, Cenderello G, Cascio A, Petrosillo N, Mussini C. Meschiari M, et al. Among authors: barchiesi f. Int J Infect Dis. 2023 Jun;131:147-154. doi: 10.1016/j.ijid.2023.04.004. Epub 2023 Apr 7. Int J Infect Dis. 2023. PMID: 37030653 Free article.
Corrigendum to: "Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)" Clinical Microbiology and Infection 26 (2020) 1545-1553.
Bartoletti M, Giannella M, Scudeller L, Tedeschi S, Rinaldi M, Bussini L, Fornaro G, Pascale R, Pancaldi L, Pasquini Z, Trapani F, Badia L, Campoli C, Tadolini M, Attard L, Puoti M, Merli M, Mussini C, Menozzi M, Meschiari M, Codeluppi M, Barchiesi F, Cristini F, Saracino A, Licci A, Rapuano S, Tonetti T, Gaibani P, Ranieri VM, Viale P; PREDICO study group. Bartoletti M, et al. Among authors: barchiesi f. Clin Microbiol Infect. 2023 Jun;29(6):817. doi: 10.1016/j.cmi.2023.02.017. Epub 2023 Mar 1. Clin Microbiol Infect. 2023. PMID: 36868355 Free PMC article. No abstract available.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
82 results